U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22N2S
Molecular Weight 310.456
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PECAZINE

SMILES

CN1CCCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1

InChI

InChIKey=CBHCDHNUZWWAPP-UHFFFAOYSA-N
InChI=1S/C19H22N2S/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21/h2-5,8-11,15H,6-7,12-14H2,1H3

HIDE SMILES / InChI

Description

PECAZINE is a phenothiazine derivative that was used as an antipsychotic. It is also an allosteric inhibitor of MALT1 paracaspase activity.

CNS Activity

Approval Year

1957
114
Doses

Doses

DosePopulationAdverse events​
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
unhealthy, 20-59
n = 33
Health Status: unhealthy
Condition: schizophrenia
Age Group: 20-59
Sex: F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
n = 1
Health Status: unhealthy
Condition: depisssion
Age Group: 35
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
unhealthy, 37.1±1.5
n = 50
Health Status: unhealthy
Condition: schizophrenia
Age Group: 37.1±1.5
Sex: M+F
Population Size: 50
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
Disc. AE: Cycloplegia...
AEs leading to
discontinuation/dose reduction:
Cycloplegia (4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
900 mg multiple, oral
Highest studied dose
Dose: 900 mg
Route: oral
Route: multiple
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Disc. AE: Jaundice...
AEs leading to
discontinuation/dose reduction:
Jaundice
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis 3%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
unhealthy, 20-59
n = 33
Health Status: unhealthy
Condition: schizophrenia
Age Group: 20-59
Sex: F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
Agranulocytosis Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
n = 1
Health Status: unhealthy
Condition: depisssion
Age Group: 35
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Cycloplegia 4%
Disc. AE
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
unhealthy, 37.1±1.5
n = 50
Health Status: unhealthy
Condition: schizophrenia
Age Group: 37.1±1.5
Sex: M+F
Population Size: 50
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
Jaundice Disc. AE
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY562589
https://www.001chemical.com/chem/60-89-9
Alfa Chemistry
60-89-9
https://www.alfa-chemistry.com/cas_60-89-9.htm
Aurora Fine Chemicals LLC
K02.237.593
http://online.aurorafinechemicals.com/info?ID=K02.237.593
Chem Scene
CS-0081367
http://www.chemscene.com/60-89-9.html
Chemspace
CSSS00102561680
https://chem-space.com/CSSS00102561680
Lab Network
LN01302729
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01302729
Matrix Scientific
176622
https://www.matrixscientific.com/176622.html
MedChem Express
HY-121282
https://www.medchemexpress.com/mepazine.html
Molcore
MC562589
https://www.molcore.com/product/60-89-9
Smolecule
S538872
http://www.smolecule.com/products/s538872
THE BioTek
bt-278398
https://www.thebiotek.com/product/inhibitors/bt-278398
VladaChem
VL130984
https://www.vladachem.com/product.php?products=60-89-9
Yuhao Chemical
SY0043
http://www.chemyuhao.com/60-89-9.html
eNovation Chemicals
D931422
https://www.enovationchem.com/ProductDetails.asp?ProductID=D931422
mcule
MCULE-4399173403
https://mcule.com/MCULE-4399173403/
PubMed

PubMed

TitleDatePubMed
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010 Mar 3
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Name Type Language
PECAZINE
INN   WHO-DD  
INN  
Official Name English
10H-PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDINYL)METHYL)-
Systematic Name English
10-((1-METHYL-3-PIPERIDINYL)METHYL)-10H-PHENOTHIAZINE
Systematic Name English
MEPAZINE
MI  
Common Name English
Pecazine [WHO-DD]
Common Name English
LACUMIN
Brand Name English
P-391
Code English
PACATAL
Brand Name English
MEPASIN
Common Name English
PACATAL BASE
Common Name English
10-((1-METHYL-3-PIPERIDYL)METHYL)PHENOTHIAZINE
Systematic Name English
pecazine [INN]
Common Name English
PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDYL)METHYL)-
Systematic Name English
MPMP
Common Name English
MESAPIN
Common Name English
PAKATAL
Common Name English
NOTHIAZINE
Brand Name English
III-2318
Code English
MEPAZIN
Common Name English
MEPRAZINE
Brand Name English
PECATAL
Common Name English
PACATOL
Brand Name English
(N-METHYL-3-PIPERIDYL)METHYLPHENOTHIAZINE
Systematic Name English
MEPAZINE [MI]
Common Name English
MEPAZINE BASE
Common Name English
PAXITAL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
Code System Code Type Description
WIKIPEDIA
Pecazine
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
MERCK INDEX
m816
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID2046177
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
INN
523
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
ChEMBL
CHEMBL395110
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
FDA UNII
PH34873A38
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
NCI_THESAURUS
C76052
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
CAS
60-89-9
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
DRUG CENTRAL
1688
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
EVMPD
SUB09642MIG
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
SMS_ID
100000083023
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-490-8
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
PUBCHEM
6075
Created by admin on Fri Dec 15 16:20:52 UTC 2023 , Edited by admin on Fri Dec 15 16:20:52 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of PECAZINE
SALT/SOLVATE (PARENT)
Structure of PECAZINE ACETATE
SALT/SOLVATE (PARENT)
Structure of PECAZINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966